Dr. Liau roughly 2 years ago told us that for the Top 100 patients in the trial, the median life span was very nearly 60 months. At the time she made the statement, roughly 100 patients had entered the trial less than 60 months earlier, so every one of them, and others, could pass the 60 month mark, I believe the Top 100 median could be nearly 70 months, perhaps even higher. With this fact alone I don't believe there is a way that trial results don't look great. Remember, at 5 years only roughly 5% GBM patients survive under SOC treatment, we know we have 50, and probably many more out of 331 who've lived at least 60 months, we'll learn far more when TLD is announced, supposedly by the end of this month, but far more when Drs. Liau and Bosch present the trial data at SNO in a plenary session on November 20th.
I do not think anyone can deny the survival benefit, even if certain FDA established values fail to be met. How can anyone argue with keeping people alive. We'll see how many remain alive at the end of the trial, I believe it could be in the 70's, but if it were just 45, that would be 3 times the SOC, but there may be many others who lived more than 5 years, but have passed on. When they unblind the trial, nearly all in it will have begun treatment more than 5 years ago, a couple may be a month or two short.
Please explain to me how this trial could still go South.
Gary